GSK (NYSE:GSK) Issues FY 2026 Earnings Guidance

Key Points

• GSK guided for FY 2026 EPS of $4.90–$5.00, above the $4.79 analyst consensus, but set revenue guidance at $44.8 billion, below the $45.7 billion estimate.
• GSK’s latest quarterly earnings were mixed: EPS of $0.67 missed expectations by $0.60, while revenue of $11.14 billion exceeded estimates of $11.02 billion.
• Analysts maintain a consensus “Hold” rating with an average price target of $53.00; GSK shares recently opened at $51.97 and offer a 3.4% dividend yield.

GSK (NYSE:GSK - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 4.900-5.000 for the period, compared to the consensus EPS estimate of 4.790. The company issued revenue guidance of $44.8 billion-$44.8 billion, compared to the consensus revenue estimate of $45.7 billion. GSK also updated its FY 2031 guidance to EPS.

GSK Price Performance

Shares of NYSE:GSK opened at $51.97 on Tuesday. The company's fifty day moving average is $51.62 and its two-hundred day moving average is $53.43. The company has a market cap of $105.11 billion, a P/E ratio of 13.50, a price-to-earnings-growth ratio of 3.27 and a beta of 0.35. GSK has a 12-month low of $36.75 and a 12-month high of $61.69. The company has a quick ratio of 0.52, a current ratio of 0.79 and a debt-to-equity ratio of 0.80.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Tuesday, July 28th. The pharmaceutical company reported $0.67 EPS for the quarter, missing the consensus estimate of $1.27 by ($0.60). GSK had a return on equity of 44.28% and a net margin of 17.82%.The business had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.02 billion. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Equities analysts expect that GSK will post 4.84 earnings per share for the current fiscal year.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, July 9th. Investors of record on Friday, May 15th were paid a $0.44 dividend. This represents a $1.76 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend was Friday, May 15th. GSK's dividend payout ratio is currently 46.49%.

Analyst Upgrades and Downgrades

GSK has been the subject of a number of research reports. Royal Bank Of Canada restated an "outperform" rating on shares of GSK in a research report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of GSK in a report on Thursday, July 9th. Wall Street Zen raised shares of GSK from a "hold" rating to a "buy" rating in a research report on Saturday, June 27th. Citigroup assumed coverage on shares of GSK in a report on Friday. They set a "neutral" rating for the company. Finally, HSBC raised shares of GSK from a "reduce" rating to a "hold" rating in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $53.00.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Brighton Jones LLC acquired a new stake in shares of GSK in the 4th quarter valued at $528,000. AQR Capital Management LLC boosted its holdings in GSK by 84.4% in the first quarter. AQR Capital Management LLC now owns 40,239 shares of the pharmaceutical company's stock worth $1,559,000 after purchasing an additional 18,420 shares in the last quarter. Empowered Funds LLC increased its position in GSK by 2.1% during the first quarter. Empowered Funds LLC now owns 79,174 shares of the pharmaceutical company's stock worth $3,067,000 after buying an additional 1,598 shares during the last quarter. Rhumbline Advisers raised its holdings in GSK by 20.7% during the second quarter. Rhumbline Advisers now owns 22,209 shares of the pharmaceutical company's stock valued at $853,000 after buying an additional 3,806 shares in the last quarter. Finally, Gabelli Funds LLC lifted its position in shares of GSK by 17.8% in the second quarter. Gabelli Funds LLC now owns 7,960 shares of the pharmaceutical company's stock worth $306,000 after buying an additional 1,200 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK's core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.